Santhera Pharmaceuticals has licenced the inhaled neutrophil eleastase blocker POL6014 from Polyphor Ltd for CHF6.5m upfront and CHF121m in potential milestones.
Co-administration of an allogenic blood stem cell transplant and sorafenib cured AML patients refractive to chemotherapy and stem cell transplants alone, oncologists report in Nature Medicine.
Poxel S.A. is advancing its proof-of-concept type 2 diabetes programme imeglimin (PXL008) into Phase III studies in the US an the EU by means of a licence deal with Swiss Roivant Sciences GmbH.
Anticalin developer Pieris and Antibody-drug conjugate specialist Seattle Genetics have agreed to co-develop three bispecific cancer drugs using Seattle Genetic’s cancer targets and Pieris’ co-stimulatory agonist and anticalin platform.
Italfarmaco SpA’s Givinostat, a small molecule histone deacetylase (HDAC) inhibitor in clinical testing against several forms muscular dystrophies, is also an option to treat heart failure with preserved ejection fraction (HFpEF), a form of congestive heart failure that affects 50% of heart failure patients.
German researchers have identified a target to switch off intestinal acute graft-versus-host disease (GVHD), which occurs in about 50% of leukemia patients that have been given a allogeneic hematopoietic cell transplantation (allo-HCT).
The European Medicines Agency (EMA) has won a landmark battle about the amount of data from clinical dossiers that may be made public. The European Court of Justics (EJC) rejected the demand of three drug developers not to publish what they called confidential information under the EMA’s transparency rules.
Global health product development partnership FIND (Foundation for Innovative New Diagnostics) has announced four major diagnostics projects to combat antimicrobial resistance (AMR) in resource-poor settings.
A brand-new survey conducted by auditing and consulting firm PwC and Strategy& has found out that 80% of data protection-prone Germans would share their data in case of being diagnosed with cancer. The results show that cancer could act as a gate-opener to approaches in personalised medicine that depend on the accessiblity of patient data.
US and Dutch researchers have found that carcinogenic E. coli and B. fragilis versions in the gut of patients who developed precancerous polyps early in life trigger development of colon cancer by secreting proinflammatoy signals, depleting mucus and inducing DNA damage.